Genome biology · 2023 · 21 citations · 55 references
Life SciencesGeneticsMolecular BiologyCarcinogenesisGenome EditingMolecular OncologyNoncoding Rna In CancerRna EditingRna ModificationApobec EnzymesCancer Gene EditingDoxycycline TreatmentDoxycycline-inducible SystemsNoncoding Rna EditingRna Editing EnzymesRna Editing In DiseaseRna Editing Of Noncoding Rna
BACKGROUND: RNA editing has been described as promoting genetic heterogeneity, leading to the development of multiple disorders, including cancer. The cytosine deaminase APOBEC3B is implicated in tumor evolution through DNA mutation, but whether it also functions as an RNA editing enzyme has not been studied. RESULTS: Here, we engineer a novel doxycycline-inducible mouse model of human APOBEC3B-overexpression to understand the impact of this enzyme in tissue homeostasis and address a potential role in C-to-U RNA editing. Elevated and sustained levels of APOBEC3B lead to rapid alteration of cellular fitness, major organ dysfunction, and ultimately lethality in mice. Importantly, RNA-sequencing of mouse tissues expressing high levels of APOBEC3B identifies frequent UCC-to-UUC RNA editing events that are not evident in the corresponding genomic DNA. CONCLUSIONS: This work identifies, for the first time, a new deaminase-dependent function for APOBEC3B in RNA editing and presents a preclinical tool to help understand the emerging role of APOBEC3B as a driver of carcinogenesis.
55
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov, Serena Nik‐Zainal, David C. Wedge et al. · Nature · 2013 · 10.1K citations · Full text
Medicine, Cancer Biology, Oncology +14
The repertoire of mutational signatures in human cancer
Mi Ni Huang, Alvin Wei Tian Ng, Arnoud Boot et al. · Nature · 2020 · 3.7K citations · Full text
Life Sciences, Genetics, Oncology +14
APOBEC3B is an enzymatic source of mutation in breast cancer
Michael B. Burns, Lela Lackey, Michael A. Carpenter et al. · Nature · 2013 · 876 citations